Format
Sort by
Items per page

Send to

Choose Destination

Links from PubMed

Items: 1 to 20 of 87

1.

Chronic hepatitis C: treat or wait? Medical decision making in clinical practice.

Niederau C, Hüppe D, Zehnter E, Möller B, Heyne R, Christensen S, Pfaff R, Theilmeier A, Alshuth U, Mauss S.

World J Gastroenterol. 2012 Mar 28;18(12):1339-47. doi: 10.3748/wjg.v18.i12.1339.

2.

Factors associated with early virological response to peginterferon-α-2a/ribavirin in chronic hepatitis C.

García-Samaniego J, Romero M, Granados R, Alemán R, Jorge Juan M, Suárez D, Pérez R, Castellano G, González-Portela C.

World J Gastroenterol. 2013 Mar 28;19(12):1943-52. doi: 10.3748/wjg.v19.i12.1943.

3.

Antiviral regimen complexity index as an independent predictor of sustained virologic response in patients with chronic hepatitis C.

Galán RJ, Cidoncha EC, Martin MF, Rodriguez CC, Almeida CV, Verdugo RM.

J Manag Care Pharm. 2013 Jul-Aug;19(6):448-53.

4.

Pegylated alpha-interferon-2a plus ribavirin compared with pegylated alpha-interferon-2b plus ribavirin for initial treatment of chronic hepatitis C virus: prospective, non-randomized study.

Escudero A, Rodríguez F, Serra MA, Del Olmo JA, Montes F, Rodrigo JM.

J Gastroenterol Hepatol. 2008 Jun;23(6):861-6. doi: 10.1111/j.1440-1746.2008.05397.x. Epub 2008 Apr 19.

PMID:
18422960
5.

Pegylated interferon alpha-2a and -2b in combination with ribavirin in the treatment of chronic hepatitis C: a systematic review and economic evaluation.

Shepherd J, Brodin H, Cave C, Waugh N, Price A, Gabbay J.

Health Technol Assess. 2004 Oct;8(39):iii-iv, 1-125. Review.

6.

Negative HCV-RNA 2 weeks after initiation of treatment predicts sustained virological response to pegylated interferon alfa-2a and ribavirin in patients with chronic hepatitis C.

Christensen PB, Krarup HB, Laursen AL, Madsen PH, Pedersen C, Schlichting P, Orholm M, Ring-Larsen H, Bukh J, Krogsgaard K.

Scand J Gastroenterol. 2012 Sep;47(8-9):1115-9. doi: 10.3109/00365521.2012.694905. Epub 2012 Jun 7.

PMID:
22670704
7.

Pegylated interferon alfa and ribavirin for children with chronic hepatitis C.

Rosen I, Kori M, Eshach Adiv O, Yerushalmi B, Zion N, Shaoul R.

World J Gastroenterol. 2013 Feb 21;19(7):1098-103. doi: 10.3748/wjg.v19.i7.1098.

8.

Noncompliance with guidelines for the treatment of hepatitis C is frequent in daily practice.

Niederau C, Mauss S, Böker K, Lutz T, Heyne R, Moog G, John C, Witthöft T, Alshuth U, Hüppe D.

Eur J Gastroenterol Hepatol. 2014 Jan;26(1):65-73. doi: 10.1097/MEG.0b013e328362dd03.

PMID:
23751351
9.

Sustained virological response: a milestone in the treatment of chronic hepatitis C.

Morisco F, Granata R, Stroffolini T, Guarino M, Donnarumma L, Gaeta L, Loperto I, Gentile I, Auriemma F, Caporaso N.

World J Gastroenterol. 2013 May 14;19(18):2793-8. doi: 10.3748/wjg.v19.i18.2793.

10.

Treatment of chronic hepatitis C with peginterferon alfa-2b, plus ribavirin in end stage renal disease patients treated by hemodialysis: single Saudi center experience.

Alsaran K, Sabry A, Molhem A.

Ren Fail. 2013;35(10):1305-9. doi: 10.3109/0886022X.2013.826136. Epub 2013 Sep 24.

PMID:
24059964
11.

Factors affecting early viral load decline of Asian chronic hepatitis C patients receiving pegylated interferon plus ribavirin therapy.

Hsu CS, Liu CH, Liu CJ, Chen CL, Lai MY, Chen PJ, Chen DS, Kao JH.

Antivir Ther. 2009;14(1):45-54.

PMID:
19320236
12.
13.

Sustained virological response to pegylated interferon and ribavirin in patients with genotype 3 HCV cirrhosis.

Butt AS, Mumtaz K, Aqeel I, Shah HA, Hamid S, Jafri W.

Trop Gastroenterol. 2009 Oct-Dec;30(4):207-12.

PMID:
20426280
15.

Peginterferon plus ribavirin versus interferon plus ribavirin for chronic hepatitis C.

Hauser G, Awad T, Brok J, Thorlund K, Štimac D, Mabrouk M, Gluud C, Gluud LL.

Cochrane Database Syst Rev. 2014 Feb 28;(2):CD005441. Review.

PMID:
24585509
16.

Nitric oxide levels and sustained virological response to pegylated-interferon alpha2a plus ribavirin in chronic HCV genotype 4 hepatitis: A prospective study.

Ibrahim M, Gomaa W, Ibrahim Y, El Hadad H, Shatat M, Aleem AA, Essawy M, Fouad YM.

J Gastrointestin Liver Dis. 2010 Dec;19(4):387-92.

17.

Aminoadamantanes for chronic hepatitis C.

Lamers MH, Broekman M, Drenth JP, Gluud C.

Cochrane Database Syst Rev. 2014 May 3;(5):CD010125. doi: 10.1002/14651858.CD010125.pub2. Review.

PMID:
24793264
18.

Effectiveness and tolerability of pegylated Interferon alpha-2a and ribavirin combination therapy in Romanian patients with chronic hepatitis C: from clinical trials to clinical practice.

Gheorghe L, Grigorescu M, Iacob S, Damian D, Gheorghe C, Iacob R, Simionov I, Vadan R, Parvulescu I, Bancila I.

Rom J Gastroenterol. 2005 Jun;14(2):109-15.

19.

Addition of pentoxifylline to pegylated interferon-alpha-2a and ribavirin improves sustained virological response to chronic hepatitis C virus: a randomized clinical trial.

Jiménez-Luévano MÁ, Lerma-Díaz JM, Hernández-Flores G, Jiménez-Partida MÁ, Bravo-Cuellar A.

Ann Hepatol. 2013 Mar-Apr;12(2):248-55.

20.

Chronic hepatitis C responds poorly to combination therapy in chronic hepatis B carriers.

Senturk H, Tahan V, Canbakan B, Uraz S, Ulger Y, Ozaras R, Tabak F, Mert A, Ozbay G.

Neth J Med. 2008 May;66(5):191-5.

Supplemental Content

Support Center